|Day's Range||53.90 - 54.82|
|52 Week Range||46.01 - 77.12|
|PE Ratio (TTM)||18.75|
|Dividend & Yield||1.56 (2.90%)|
|1y Target Est||N/A|
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.